As published on nebius.com. Captured by usedby on Oct 7, 2026.
What happened
Compugen, an immuno-oncology biotech, used Nebius AI Cloud GPUs to train a model that predicts tertiary lymphoid structures (TLS) at the single-cell level from tumor expression data. The model is intended to be integrated into its Unigen platform to run inference across datasets that lack spatial information.
Summary written by usedby from the source page, in English. The figures are those of Nebius AI Cloud and Compugen, not ours.
Starting as an educational partnership at Nebius Academy, the collaboration with Compugen quickly expanded into full‑scale training on Nebius AI Cloud, turning a classroom prototype into a production-grade research model that focuses on tertiary lymphoid structures (TLS)
Nebius gave us powerful GPUs, a smooth interface and competitive pricing to train large-scale models on sensitive biological data. It’s a great match for AI in biotech
What the story claims, and what we checked
We compared the story with its live page on Oct 7, 2026.
- The passage quoted aboveCheckedCopied word for word from the page, near the name of Compugen.
- Compugen uses Nebius AI CloudCheckedConfirmed line. Latest check across sources: Oct 7, 2026.
- The result itselfNot checkedWe quote it; we did not measure it.




